** Shares of drug developer Dyne Therapeutics down about 4% at $31.2 premarket
** J.P. Morgan downgrades stock to "Neutral" rating from "Overweight", cuts PT to $35 from $43
** Brokerage skeptical if additional results from an early-to-mid stage trial testing DYNE-101 for a genetic muscular disorder would "fundamentally move the likelihood of success materially higher" or add near-term value
** Adds recent safety concerns over another early-to-mid stage trial testing DYNE-251 for a rare muscular degeneration disorder could keep DYN stock range bound over mid-term
** Nine of 10 brokerages rate the stock "buy" or higher while one rates "hold"; their median PT is $52.5 - LSEG data
** As of last close, stock more than doubled YTD vs 7.65% gain in Nasdaq Biotechnology Index
(Reporting by Sruthi Narasimha Chari in Bengaluru)
((Sruthinarasimha.chari@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.